Tevogen Bio Holdings Stock Cash Flow From Operations
| TVGN Stock | 1.31 0.06 4.38% |
Tevogen Bio Holdings fundamentals help investors to digest information that contributes to Tevogen Bio's financial success or failures. It also enables traders to predict the movement of Tevogen Stock. The fundamental analysis module provides a way to measure Tevogen Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Tevogen Bio stock.
Tevogen |
Tevogen Bio Holdings Company Cash Flow From Operations Analysis
Tevogen Bio's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Tevogen Bio Cash Flow From Operations | (1.38 M) |
Most of Tevogen Bio's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Tevogen Bio Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Tevogen Cash Flow From Operations Driver Correlations
Understanding the fundamental principles of building solid financial models for Tevogen Bio is extremely important. It helps to project a fair market value of Tevogen Stock properly, considering its historical fundamentals such as Cash Flow From Operations. Since Tevogen Bio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Tevogen Bio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Tevogen Bio's interrelated accounts and indicators.
Click cells to compare fundamentals
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Tevogen Bio Holdings has (1.38 Million) in Cash Flow From Operations. This is 100.26% lower than that of the Biotechnology sector and 102.2% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 100.14% higher than that of the company.
Tevogen Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Tevogen Bio's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Tevogen Bio could also be used in its relative valuation, which is a method of valuing Tevogen Bio by comparing valuation metrics of similar companies.Tevogen Bio is currently under evaluation in cash flow from operations category among its peers.
Tevogen Fundamentals
| Return On Asset | -0.83 | ||||
| Current Valuation | 258.98 M | ||||
| Shares Outstanding | 164.61 M | ||||
| Shares Owned By Insiders | 96.61 % | ||||
| Shares Owned By Institutions | 4.58 % | ||||
| Number Of Shares Shorted | 774.71 K | ||||
| EBITDA | 188.71 K | ||||
| Net Income | (67.33 K) | ||||
| Total Debt | 1.63 M | ||||
| Cash Flow From Operations | (1.38 M) | ||||
| Short Ratio | 0.07 X | ||||
| Beta | 0.48 | ||||
| Market Capitalization | 164.61 M | ||||
| Total Asset | 17.04 M | ||||
| Retained Earnings | (17.38 M) | ||||
| Working Capital | (2.65 M) | ||||
| Net Asset | 17.04 M |
About Tevogen Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Tevogen Bio Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tevogen Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tevogen Bio Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Tevogen Bio
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tevogen Bio position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tevogen Bio will appreciate offsetting losses from the drop in the long position's value.Moving together with Tevogen Stock
Moving against Tevogen Stock
| 0.84 | ELAN | Elanco Animal Health | PairCorr |
| 0.7 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.69 | TAK | Takeda Pharmaceutical | PairCorr |
| 0.67 | HLN | Haleon plc | PairCorr |
| 0.57 | ZTS | Zoetis Inc | PairCorr |
The ability to find closely correlated positions to Tevogen Bio could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tevogen Bio when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tevogen Bio - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tevogen Bio Holdings to buy it.
The correlation of Tevogen Bio is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tevogen Bio moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tevogen Bio Holdings moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tevogen Bio can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Tevogen Bio Piotroski F Score and Tevogen Bio Altman Z Score analysis. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tevogen Bio. If investors know Tevogen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tevogen Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Return On Assets (0.83) |
The market value of Tevogen Bio Holdings is measured differently than its book value, which is the value of Tevogen that is recorded on the company's balance sheet. Investors also form their own opinion of Tevogen Bio's value that differs from its market value or its book value, called intrinsic value, which is Tevogen Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tevogen Bio's market value can be influenced by many factors that don't directly affect Tevogen Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tevogen Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine if Tevogen Bio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tevogen Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.